{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:19:57Z","timestamp":1791353997132,"version":"4.3.1"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular disease is the leading cause of morbidity and mortality in the elderly. Managing cardiovascular risk in this group is uniquely challenging due to physiological changes, multimorbidity, polypharmacy, and frailty, compounded by the under-representation of older adults in clinical trials Recent advances, including the SCORE2-OP risk stratification tool and emerging therapies such as sodium\u2013glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have reshaped approaches to risk reduction. This review synthesizes the latest evidence and guideline recommendations for the management of hypertension, dyslipidaemia, diabetes, obesity, and antithrombotic therapy in older patients, with particular attention to frailty, adherence challenges, and individualized care. By addressing the complexities of cardiovascular risk management in older adults, this paper provides a practical framework for clinicians navigating this critical area.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwag316","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:13:11Z","timestamp":1781611991000},"page":"iii13-iii25","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular risk management in the elderly: a dilemma in daily clinical practice"],"prefix":"10.1093","volume":"33","author":[{"given":"Gian Marco","family":"Dacquino","sequence":"first","affiliation":[{"name":"Cardiovascular Department, I.R.C.C.S. MultiMedica, Via Milanese, 300, 20099, Sesto san Giovanni , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Galati","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, I.R.C.C.S. MultiMedica, Via Milanese, 300, 20099, Sesto san Giovanni , Milan ,","place":["Italy"]},{"name":"School of Medicine and Surgery, University of Milano Bicocca , Piazza dell'Ateneo Nuovo, 1, 20126 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Genovese","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, I.R.C.C.S. MultiMedica, Via Milanese, 300, 20099, Sesto san Giovanni , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Ferrari","family":"Bravo","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, I.R.C.C.S. MultiMedica, Via Milanese, 300, 20099, Sesto san Giovanni , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-8829","authenticated-orcid":false,"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina ,","place":["Italy"]},{"name":"UOC UTIC Emodinamica e Cardiologia, Santa Maria Goretti Hospital , Latina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina ,","place":["Italy"]},{"name":"UOC UTIC Emodinamica e Cardiologia, Santa Maria Goretti Hospital , Latina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1789-8657","authenticated-orcid":false,"given":"Roberto Franco Enrico","family":"Pedretti","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, I.R.C.C.S. MultiMedica, Via Milanese, 300, 20099, Sesto san Giovanni , Milan ,","place":["Italy"]},{"name":"School of Medicine and Surgery, University of Milano Bicocca , Piazza dell'Ateneo Nuovo, 1, 20126 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082620015341200_zwag316-B1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082620015341200_zwag316-B2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082620015341200_zwag316-B3","first-page":"894","article-title":"Review on the management of cardiovascular risk factors in the elderly","volume":"19","author":"Gonz\u00e1lez-Cola\u00e7o Harmand","year":"2022","journal-title":"J Geriatr Cardiol"},{"key":"2026082620015341200_zwag316-B4","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026082620015341200_zwag316-B5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026082620015341200_zwag316-B6","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026082620015341200_zwag316-B7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.HYP.37.3.869","article-title":"Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III","volume":"37","author":"Franklin","year":"2001","journal-title":"Hypertension"},{"key":"2026082620015341200_zwag316-B8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","article-title":"Treatment with multiple blood-pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study","volume":"175","author":"Benetos","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026082620015341200_zwag316-B12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ageing\/afz072","article-title":"Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis","volume":"48","author":"Todd","year":"2019","journal-title":"Age Ageing"},{"key":"2026082620015341200_zwag316-B13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/CIRCRESAHA.118.313236","article-title":"Hypertension management in older and frail older patients","volume":"124","author":"Benetos","year":"2019","journal-title":"Circ Res"},{"key":"2026082620015341200_zwag316-B14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1056\/NEJMoa2508157","article-title":"Reduction of antihypertensive treatment in nursing home residents","volume":"393","author":"Benetos","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/jama.279.11.839","article-title":"Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group","volume":"279","author":"Whelton","year":"1998","journal-title":"JAMA"},{"key":"2026082620015341200_zwag316-B16","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","article-title":"Primary prevention with statins in the elderly","volume":"71","author":"Mortensen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026082620015341200_zwag316-B18","article-title":"Treatment gaps in the implementation of LDL-cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026082620015341200_zwag316-B19","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026082620015341200_zwag316-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026082620015341200_zwag316-B21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B22","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B23","first-page":"2","article-title":"Statins in the elderly: an answer at last?","volume":"42","author":"Zoungas","year":"2019","journal-title":"Aust Prescr"},{"key":"2026082620015341200_zwag316-B24","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/jgs.18312","article-title":"Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE): trial design and rationale","volume":"71","author":"Joseph","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"2026082620015341200_zwag316-B25","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2022","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrneurol.2015.35","article-title":"Statins, cognition, and dementia\u2014systematic review and methodological commentary","volume":"11","author":"Power","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"2026082620015341200_zwag316-B31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","article-title":"Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies","volume":"29","author":"Olmastroni","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026082620015341200_zwag316-B32","doi-asserted-by":"crossref","first-page":"e11304","DOI":"10.1097\/MD.0000000000011304","article-title":"Statins use and risk of dementia: a dose-response meta-analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026082620015341200_zwag316-B33","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026082620015341200_zwag316-B34","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc24-S013","article-title":"13. Older adults: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026082620015341200_zwag316-B35","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082620015341200_zwag316-B36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jdiacomp.2017.02.014","article-title":"Liberating A1c goals in older adults may not protect against the risk of hypoglycemia","volume":"31","author":"Munshi","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2026082620015341200_zwag316-B37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B41","first-page":"95","article-title":"Use of SGLT2 inhibitors in older adults: scientific evidence and recommendations","volume":"41","author":"Custodio","year":"2024","journal-title":"Drugs Aging"},{"key":"2026082620015341200_zwag316-B42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B47","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B48","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurpub\/ckx143","article-title":"Prevalence of adult overweight and obesity in 20 European countries, 2014","volume":"28","author":"Marques","year":"2018","journal-title":"Eur J Public Health"},{"key":"2026082620015341200_zwag316-B50","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"key":"2026082620015341200_zwag316-B51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2018.12440","article-title":"Aging, cell senescence, and chronic disease: emerging therapeutic strategies","volume":"320","author":"Tchkonia","year":"2018","journal-title":"JAMA"},{"key":"2026082620015341200_zwag316-B52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/VHRM.S168946","article-title":"Obesity paradox in cardiovascular disease: where do we stand?","volume":"15","author":"Carbone","year":"2019","journal-title":"Vasc Health Risk Manag"},{"key":"2026082620015341200_zwag316-B53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pcad.2016.01.008","article-title":"Obesity and prevalence of cardiovascular diseases and prognosis\u2014the obesity paradox updated","volume":"58","author":"Lavie","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"2026082620015341200_zwag316-B54","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"2026082620015341200_zwag316-B55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026082620015341200_zwag316-B56","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ajcn\/82.5.923","article-title":"Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society","volume":"82","author":"Villareal","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"2026082620015341200_zwag316-B57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40520-024-02701-1","article-title":"Effects of semaglutide on body composition, glycaemic control and cardiovascular risk in older obese patients with type 2 diabetes: a real-world pilot study","volume":"36","author":"Liu","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"2026082620015341200_zwag316-B58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B59","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B60","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2026082620015341200_zwag316-B61","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082620015341200_zwag316-B62","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2026082620015341200_zwag316-B63","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","article-title":"World Health Organization 2020 guidelines on physical activity and sedentary behaviour","volume":"54","author":"Bull","year":"2020","journal-title":"Br J Sports Med"},{"key":"2026082620015341200_zwag316-B64","article-title":"Dose-response associations between accelerometry measured physical activity and sedentary time and all-cause mortality: systematic review and harmonised meta-analysis","volume":"366","author":"Ekelund","year":"2019","journal-title":"BMJ"},{"key":"2026082620015341200_zwag316-B65","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1001\/jama.2014.5616","article-title":"Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial","volume":"311","author":"Pahor","year":"2014","journal-title":"JAMA"},{"key":"2026082620015341200_zwag316-B66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/gerona\/gly110","article-title":"Frailty and multimorbidity: a systematic review and meta-analysis","volume":"74","author":"Vetrano","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026082620015341200_zwag316-B67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026082620015341200_zwag316-B68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jgs.15634","article-title":"Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging workshop","volume":"67","author":"Schwartz","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2026082620015341200_zwag316-B69","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","article-title":"Multimorbidity in older adults with cardiovascular disease","volume":"71","author":"Forman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026082620015341200_zwag316-B70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIR.0000000000000380","article-title":"Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society","volume":"133","author":"Rich","year":"2016","journal-title":"Circulation"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/Supplement_3\/iii13\/70784266\/zwag316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/Supplement_3\/iii13\/70784266\/zwag316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:02:10Z","timestamp":1787788930000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/Supplement_3\/iii13\/8770346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag316","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]}}}